Varex Imaging Corporation VREX NASDAQ · Healthcare · United States
$18.13 +0.17% +$0.03
Summary
39 / 100 · Bulios Score
What speaks for it
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- Revenue fell by 0.6% a year over the last 3 years.
- You pay 34.8 USD for 1 USD of yearly profit, a lot for its sector.
- It reports a profit, yet spends more cash than it brings in.
- Operating profit covers the interest on its debt only 1.7 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 34.8 USD for 1 USD of yearly profit. Over the last five years it was 38.4 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.7% a year over 5 years. Over the last 3 years it fell by 0.6% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 66 USD
- Research and development 11 USD
- Sales and administration 15 USD
- Taxes and other 5.8 USD
- Net profit 2.6 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 2.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 2
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $14.5 is 20% below today's price. 29% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Medical Segment 72%
- Industrial Segment 28%
By region
- EMEA 26%
- Americas 25%
- Asia Pacific 25%
- UNITED STATES 24%
Medical Segment brings in 72% of revenue.
Segments in detail